Lipid lowering drug and other toxic myopathies;Lipidsenker- und andere toxische Myopathien

Internist

Volumn 46, Issue 11, 2005, Pages 1198-1206

  Schoser, B G H ^a   Pongratz, D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Lipid lowering drug myopathy; Myopathy; Rhabdomyolysis; Toxic myopathy

Indexed keywords

ALCOHOL; ANTILIPEMIC AGENT; CERIVASTATIN; CORTICOSTEROID; CREATINE KINASE; DEXAMETHASONE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISONE; TOXIN; TRIAMCINOLONE;

ALCOHOL ABUSE; DISEASE CLASSIFICATION; EXERCISE TOLERANCE; FREQUENCY ANALYSIS; HEALTH CARE UTILIZATION; HUMAN; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROPATHY; PARESIS; RECOGNITION; REVIEW; RHABDOMYOLYSIS; SYMPTOM; TISSUE STRUCTURE; TOXIN SYNTHESIS;

ANTILIPEMIC AGENTS; ETHANOL; HUMANS; MUSCULAR DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 28744454293     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1490-x     Document Type: Review

References (31)

1. Preedy VR, Paice A, Mantle D, Dhillon AS, Palmer TN, Peters TJ (2001) Alcoholic myopathy: biochemical mechanisms. Drug Alcohol Depend 63: 199-205
2. Owczarek J, Jasinska M, Orszulak-Michalak D (2005) Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57: 23-34
3. Sieb JP, Gillessen T (2003) latrogenicand toxic myopathies. Muscle Nerve 27: 142-156
4. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K (2001) Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56 [Suppl 1]: 24-28
5. Bowyer SL, LaMothe MP, Hollister JR (1985) Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 76: 234-242
6. Batchelor TT, Taylor LR Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology 48: 1234-1238
7. Falduto MT, Young AP, Hickson RC (1992) Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 263: E1157-1163
8. Ford ES, Mokdad AH, Giles WH, Mensah GA (2003) Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults; findings from the National Health and Nutrition Examination Survey. Circulation 107: 2185-2189
9. Menge T, von Büding HC, Zamvil SS, Hartung HP, Kieseier BC, Stüve O (2005) Staline zur Behandlung von Erkrankungen des zentralen Nervensystems. Eine Standortbestimmung aus Forschung und Klinik. Nervenarzt 76: 426-437
10. Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. BMJ 323: 359
11. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Lipid lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12: 565-569
12. Graham DJ, Staffa JA, Shatin D et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590
13. Jones PH, Davidson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95: 120-122
14. Thompson PD, Clarkson R Karas RH (2003) Statin-associated myopathy. JAMA 289: 1681-1690
15. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G (2004) A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 17: 459-465
16. Finsterer J (2003) Fibrat-/Statin-Myopathie. Nervenarzt 74: 115-122
17. Köller H, Neuhaus O, Schroeter M, Hartung HP (2005) Myopathien unter Therapie mit Lipidsenkern. Nervenarzt 76: 212-217
18. Vasconcelos OM, Campbell WW (2004) Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30: 803-807
19. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD (2004) Statin-associated exacerbation of myasthenia gravis. Neurology 63: 2188
20. Chong PH, Boskovich A, Stevkovic N, Bartt RE (2004) Statin-induced peripheral neuropathy: review of the literature. Pharmacotherapy 24: 1194-1203
21. Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM (2004) The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 14: 237-245
22. Langsjoen PH, Langsjoen AM (2003) The clinical use of HMG CoA-reductase inhibitors and the associacited depletion of coenzyme Q10. A review of animal and human publications. Biofactors 18: 101-111
23. Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F (2005) Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 62: 317-320
24. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR (2004) Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200: 237-250
25. Fielding C, Fielding PE (2000) Cholesterol and caveolae: structural and functional relationships. Biochem Biophys Acta 29: 210-222
26. Betz RC, Schoser BGH, Kasper D et al. (2001) Mutations in CAV-3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 28: 218-219
27. Sumi D, Hayashi T, Thakur NK et al. (2001) A HMG-CoA reductase inhibitor possesses a potent antiatherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atheriosclerosis 155: 347-357
28. van Meer G (2001) Caveolin, cholesterol, and lipid droplets? J Cell Biol 152: F29-34
29. Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116: 408-416
30. Pasternak RC, Smith SC, Bairey-Merz JI, Grundy SM, Cleeman JI, Lenfant C (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33: 2337-2341
31. Arzneimittelkommission der deutschen Ärzteschaft (2004) Aus der UAW-Datenbank: Myopathien bzw. Leberreaktionen unter Ezetimib. Dtsch Ärztebl 101: A959